Results 271 to 280 of about 54,430 (317)

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

[Vasodilator agents and the vascular endothelium].

Annales de cardiologie et d'angeiologie, 1990
The recent discovery of endothelium-derived relaxation factor (EDRF) has altered the traditional classification of vasodilators used in angina pectoris and heart failure. If a vasodilator induces release of EDRF from the epithelium it is classified as endothelium-dependent, if not it is independent.
openaire   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Recent progress in the treatment of cancer in children

Ca-A Cancer Journal for Clinicians, 2021
Theodore W Laetsch
exaly  

Vasodilators and hypotensive agents

1996
R F Armstrong, W Aveling, E M Grundy
openaire   +1 more source

Improving the outcome for children with cancer: Development of targeted new agents

Ca-A Cancer Journal for Clinicians, 2015
Peter C Adamson
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Ca-A Cancer Journal for Clinicians, 2016
Giuseppe Curigliano, Daniela Maria Cardinale, Susan Dent   +2 more
exaly